{
  "created_at": "Sat Nov 20 8:14:56 +0000 2021",
  "id_str": "1461952984271708161",
  "full_text": "In America, pharmaceutical companies are, in effect, the price makers. If passed, a bill that the Democrats are trying to fast-track through Congress would allow the government to have some say in drug prices for the first time  https://t.co/HQnpiYMXst",
  "display_text_range": [
    0,
    252
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/HQnpiYMXst",
        "expanded_url": "https://econ.st/3Fu8qry",
        "display_url": "econ.st/3Fu8qry",
        "indices": [
          229,
          252
        ]
      }
    ]
  },
  "user": {
    "name": "The Economist",
    "screen_name": "TheEconomist",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/879361767914262528/HdRauDM-_normal.jpg"
  },
  "retweet_count": 37,
  "favorite_count": 86,
  "possibly_sensitive": false,
  "original_created_at": "Sat Nov 20 07:02:07 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "アメリカでは、製薬会社は実質的に価格決定者です。民主党が議会を早送りしようとしている法案が可決されれば、政府が初めて医薬品の価格に口を出すことができるようになります。https://t.co/HQnpiYMXst"
    },
    {
      "locale": "zh",
      "full_text": "在美国，制药公司实际上是价格的制定者。如果获得通过，民主党人正试图在国会快速通过的一项法案将首次允许政府对药品价格有一定的发言权，https://t.co/HQnpiYMXst。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "在美國，製藥公司實際上是價格的制定者。如果獲得通過，民主黨人正試圖在國會快速通過的一項法案將首次允許政府對藥品價格有一定的發言權，https://t.co/HQnpiYMXst。"
    }
  ]
}